Treatment of pneumonia
Pro Research Analysisby 
Searched over 200M research papers
Pneumonia Treatment Approaches: Antibiotics, Antivirals, and Individualized Care
Empiric Antibiotic Therapy for Community-Acquired Pneumonia (CAP)
For community-acquired pneumonia, the first step is usually empiric antibiotic therapy, meaning treatment is started before the exact cause is known. Commonly recommended antibiotics include macrolides, fluoroquinolones, or doxycycline, with the choice guided by clinical guidelines and local resistance patterns. Hospitalized patients should be switched from intravenous to oral antibiotics once they are stable and able to tolerate oral medications. Shorter courses of antibiotics (as little as 3–5 days for mild to moderate cases) are often as effective as longer courses, reducing side effects and resistance risks. Follow-up and early transition to oral therapy are important for effective management and cost-effectiveness 456.
Hospital-Acquired and Health-Care-Associated Pneumonia: Broad-Spectrum and Targeted Therapy
Hospital-acquired pneumonia (HAP) and health-care-associated pneumonia (HCAP) are often caused by a wider range of bacteria, including drug-resistant strains like MRSA and Pseudomonas aeruginosa. Early, appropriate broad-spectrum antibiotics are critical, and therapy should be tailored based on local resistance patterns, disease severity, and specific risk factors. Newer antibiotics such as telavancin and ceftobiprole medocaril offer additional options, especially for resistant pathogens. For HAP caused by Pseudomonas, combination therapy (e.g., an antipseudomonal β-lactam plus an aminoglycoside or fluoroquinolone) is recommended to prevent resistance and improve outcomes 19.
Special Considerations for Drug-Resistant Pathogens
In critically ill patients with pneumonia caused by drug-resistant Acinetobacter baumannii, certain treatments have shown better survival and cure rates than standard intravenous colistin. These include sulbactam (alone or high-dose), fosfomycin plus colistin, inhaled plus intravenous colistin, and high-dose tigecycline. Sulbactam and inhaled plus intravenous colistin are particularly effective for survival and clinical cure, while fosfomycin plus colistin and sulbactam are superior for microbiological eradication .
Antiviral and Adjunctive Therapies for Viral Pneumonia
Viral pneumonia, such as that caused by influenza or RSV, is treated with antiviral drugs like ribavirin, adobiravir, and oseltamivir. However, resistance is a growing problem. Natural compounds (e.g., astragalus saponins, Houttuynia cordata flavonoids, tea theaflavin-gallates) may support antiviral therapy by boosting immune responses and inhibiting viral replication, but they are not substitutes for standard antivirals .
Pediatric Pneumonia: WHO Recommendations
For non-severe pneumonia in children, amoxicillin is the preferred first-line antibiotic, given twice daily for 3–5 days. Co-trimoxazole may be used in some settings. If treatment fails, high-dose amoxicillin–clavulanic acid, with or without a macrolide for older children, is recommended as a second-line option. Treatment failure should prompt a systematic review for alternative diagnoses or non-adherence .
Optimizing Treatment in Critically Ill Patients
In severe or ICU cases, early and appropriate antimicrobial therapy is crucial. Identifying the causative pathogen helps guide therapy and supports antimicrobial stewardship. Diagnostic tools like procalcitonin testing, MRSA nares screening, and rapid PCR panels can help optimize antibiotic use and reduce unnecessary exposure, minimizing resistance and side effects 310.
Conclusion
Effective pneumonia treatment relies on early, appropriate empiric therapy tailored to the likely pathogens and patient risk factors. Shorter antibiotic courses are often sufficient for mild to moderate cases, while severe or drug-resistant infections may require combination or newer therapies. Antiviral drugs and supportive natural compounds are important for viral pneumonia. In all cases, regular reassessment and stewardship practices are essential to improve outcomes and limit resistance 1234+6 MORE.
Sources and full results
Most relevant research papers on this topic